免疫检查点抑制剂治疗肺腺癌脑转移的临床疗效评估及危险因素分析

核心信息

  • 论文英文标题: The clinical outcome and risk factors analysis of immune checkpoint inhibitor-based treatment in lung adenocarcinoma patients with brain metastases
  • 期刊: TRANSL LUNG CANCER R
  • 发表年份: 2022
  • DOI: 10.21037/tlcr-22-260
  • PMID/PMCID: 35529783; PMC9073749

研究概览

This real-word study is aimed to evaluate the clinical outcome of immune checkpoint inhibitor (ICI)-based treatment in lung adenocarcinoma patients with brain metastases (BMs) and explore potential risk factors, with a focus on the spatial distribution of BMs as previous studies suggested spatial heterogeneity on the brain immune microenvironment. This real-word study is aimed to evaluate the clinical outcome of immune checkpoint inhibitor (ICI)-based treatment in lung adenocarcinoma patients with brain metastases (BMs) and explore potential risk factors, with a focus on the spatial distribution of BMs as previous studies suggested spatial heterogeneity on the brain immune microenvironment.

核心发现

Six upregulated miRNAs were identified in patients with cerebellum metastases (N=8) compared with those without (N=7).

The enrichment of differentially expression genes in the KEGG pathways indicated upregulated sulfur metabolism pathway in patients with cerebellum metastases.

研究设计

Advanced lung adenocarcinoma patients with non-oncogene-addicted, who received ICI monotherapy or plus chemotherapy, were enrolled.

Intergroup comparisons were performed using Pearson's χ2 or Fisher's exact tests for categorical variables.

The progression-free survival (PFS) was estimated using Kaplan-Meier method and compared using log-rank test.

Echo Biotech 角色

血浆外泌体miRNA

关联平台: Exoomics®, Research Reagents & Tools

关联服务与能力: Biofluid EV Isolation & Purification, Research Reagent / Product Supply

关联产品或试剂: Exosupur® EV Isolation/Purification Kit

参考文献

原始论文: The clinical outcome and risk factors analysis of immune checkpoint inhibitor-based treatment in lung adenocarcinoma patients with brain metastases Translational Lung Cancer Research. 2022. DOI: 10.21037/tlcr-22-260. PMID/PMCID: 35529783; PMC9073749.